• Anaplan

  Participated · Equity · Jan 2016

  Anaplan offers cloud-based connected planning solutions to speed and improve organizational planning and decision-making. The company also provides support, training and planning transformation advisory services. Led by President and CEO Frank Calderoni, Anaplan serves customers through a global footprint of 18 offices and more than 150 expert partners. The company raised $60M in a Series F and has now raised $300M in total capital. Management plans to use the proceeds to scale sales and customer success, enable partners, expand internationally with a focus on key lines of business, and grow the development team to accelerate product evolution and innovation. Anaplan sells financial planning as a service to large organizations, enabling shared planning and collaboration across stakeholders. The product competes with incumbent enterprise vendors such as Oracle, IBM and SAP and, to some degree, with Microsoft Excel. The company reports over 400 customers in 20 countries and plans to expand internationally, with a particular focus on growing in India. Management says this will be the last private round before an IPO in the “not-too-distant future” and has hired James Budge as CFO. Over the next year Anaplan plans to add engineering and go-to-market personnel and to build up the cloud infrastructure that supports the product, and expects about 900 employees by year-end. Financially, the company has raised a total just over $234 million across all rounds after the latest financing. Anaplan offers a cloud-based planning application that lets companies build and run complex planning models without managing code or infrastructure. The company introduced Anaplan Hub, a marketplace for pre-designed planning models that customers can preview, review, download and adapt, which is planned to go live this summer. CEO Frederic Laluyaux positions the Hub as an app-store–style community to help planners share models and accelerate deployment. Anaplan counts customers including HP, Kimberly-Clark, Procter & Gamble and Pandora. The product aims to create a “planning cloud” analogous to Salesforce’s sales cloud or Workday’s HR cloud, enabling users to plan where and when they need to. With the Hub and community focus, Anaplan is emphasizing both product functionality and network effects among planners. The company has significantly increased its funding to support these initiatives. Anaplan offers a cloud-based, in-memory modeling and planning platform that targets finance, sales and operations teams. Its applications let business users dynamically test and operationalize plans, manage multi-dimensional models, collaborate across functions and regions, and share insights via a built-in community. The company has introduced packaged offerings for finance, marketing, operations and HR, plus a sales performance management suite covering quota, territory and commissions management, real-time quoting and price optimization. Clients named in the article include McAfee, Diageo, Kimberly-Clark Eastern Europe and Pandora. Anaplan is led by CEO Fred Laluyaux and has expanded its presence in Europe, acquiring Vue Analytics and opening a European headquarters in Paris. The company plans to use new funding to expand into the UK, France, Sweden and Singapore, build new data centers globally and accelerate development of its business-user-centric platform. Anaplan provides a cloud platform that lets business users create rich, self-service planning and performance-management applications in days rather than months. The platform supports enterprise applications such as quota management, sales commission management, forecasting, project tracking, budgeting, and network capacity planning. The company emphasizes reducing reliance on traditional IT and consultants by enabling nontechnical users to configure solutions. Anaplan plans to use new funding to expand its sales force, enter new markets and build a global partner network. The company was founded in 2008 and is led by CEO Guy Haddleton and Chief Architect Michael Gould. It is based in San Francisco, California.

• SevOne

  Participated · Series C · Sep 2015

  SevOne provides digital infrastructure management solutions built on its patented SevOne Cluster architecture, which aggregates massive amounts of data to deliver real-time insights. The company serves large datacenter and network operators, carriers, and enterprises and cites penetration among top customers (40% of top technology companies, 50% of top fixed and mobile broadband carriers, and 60% of top investment services firms). SevOne recently raised $50 million in a Series C financing to accelerate growth into new technologies and markets. The company said it will invest in new technologies and markets and is constructing a 48,000 square-foot research and development center on the University of Delaware STAR Campus, opening in October. SevOne has offices in Boston, Philadelphia, London, and Bulgaria and was named a Visionary in Gartner's 2015 Magic Quadrant for Network Performance Monitoring and Diagnostics. SevOne provides real-time infrastructure and performance management using a peer-to-peer networking architecture and big-data clusters, delivered as a hardware or virtual appliance. Its P2P system uses a single common code base and image so distributed appliances are aware of each other and can monitor millions of elements across networking technologies via a web interface. SevOne charges $5 per monitored element and counts customers including Comcast and Thomson Reuters; it was ranked 75th fastest-growing company in North America on Deloitte’s 2012 Technology Fast 500. The company currently has about 140 employees and plans to scale to several hundred by the end of the year, hiring salespeople and developers to reach the mid-market. To expand beyond very large enterprise customers into mid-sized enterprises, SevOne intends to build a deeper inside-sales organization and make the product easier to consume. It raised $150 million from Bain Capital to scale its IT management offering and pursue an initial public offering.

• Translate Bio

  Participated · Series B · Jul 2015

  RaNA Therapeutics is developing a new class of medicines that target RNA to selectively upregulate protein expression in cells. The company’s proprietary platforms focus on epigenetic gene upregulation and messenger RNA (mRNA) stabilization. RaNA is advancing programs directed at spinal muscular atrophy and Friedreich's ataxia and plans IND-enabling studies and lead optimization for priority programs. Proceeds from its recent financing will be used to expand chemistry and oligonucleotide synthesis capabilities and support preclinical development. The company anticipates having up to two novel therapies in the clinic in 2017. RaNA highlights its foundational patents, technology, and experienced leadership as assets to rapidly advance a pipeline across rare genetic, inflammatory, oncologic, metabolic, and neurodegenerative indications. RaNA Therapeutics is developing a platform to selectively activate target genes by modulating long non-coding RNAs (lncRNAs) that interact with the PRC2 epigenetic repressor complex. The company’s lead approach is designed to block PRC2 binding to specific lncRNA regions, thereby inducing expression of associated target genes. RaNA’s technology was licensed exclusively from Massachusetts General Hospital and is based on discoveries from Scientific Founder Jeannie T. Lee, MD, PhD. The firm was co-founded by Atlas Venture, Arthur Krieg, and Dr. Lee and was seed-funded by Atlas Venture the prior year. RaNA intends to use its recent financing to accelerate R&D across multiple disease areas, expand its intellectual property estate in lncRNA, and grow the core team. The company also announced board additions from investors as it advances preclinical development of its programs.

• Giosis

  Participated · Series A · Jul 2015

  Giosis operates Qoo10, a B2C e-commerce marketplace with sites in Singapore, Japan, Indonesia, Malaysia, Hong Kong, and China. Qoo10 claims 17.6 million registered users and reported $408 million in gross merchandise volume last year. The company plans to boost operations in Asia, with particular expansion into Indonesia and broader Southeast Asia. Planned uses of capital include marketing, deploying independent storefronts for merchants, and improving mobile apps such as messenger QTalk to migrate more traffic to mobile. Qoo10 is also investing in logistics partners to speed delivery, exploring in-store pickup, and pursuing online-to-offline strategies. Singapore Press Holdings will partner with Qoo10 on verticals like advertising and classifieds to support those efforts.

• REGENXBIO

  Led · Series D · May 2015

  Regenxbio is a Rockville, Maryland–based gene therapy-focused biotech leveraging its proprietary NAV® Technology to develop AAV-based treatments for CNS and retinal diseases, including Hurler Syndrome (MPS I), Hunter Syndrome (MPS II) and wet age-related macular degeneration. Led by President and CEO Ken Mills, the company is advancing its lead programs through clinical development and has granted 16 commercial licenses for NAV Technology-based treatments. Regenxbio intends to use new funds to advance lead programs through clinical development, build out clinical and manufacturing infrastructure, expand its team and add to its pipeline of innovative AAV gene therapies. The company closed a $70.5M Series D round that brought total funding to more than $110M. In conjunction with the financing, Dr. Edgar Engleman, Managing Partner of Vivo Capital, joined Regenxbio’s board of directors. Regenxbio leverages its proprietary NAV® Technology to develop gene therapies targeting central nervous system diseases such as Hurler Syndrome (MPS I) and Hunter Syndrome (MPS II). The company is advancing lead programs through clinical development and has plans to build out clinical and manufacturing infrastructure while expanding its team. Regenxbio formed Dimension Therapeutics with Fidelity Biosciences to focus on NAV-based gene therapies for liver-directed rare diseases. Led by President and CEO Ken Mills, the company is positioning its platform to address multiple diseases where gene therapy can make a meaningful difference. Regenxbio is headquartered in Washington, DC. The company completed a financing to support these development and infrastructure goals.

No current team members are available.